Mechanisms of Thrombogenesis in Polycythemia Vera

Overview

Journal Blood Rev

Publisher Elsevier

Specialty Hematology

Date 2015 Jan 12

PMID 25577686

Citations 38

Authors

Michael H Kroll

Laura C Michaelis

Srdan Verstovsek

Affiliations

Soon will be listed here.

Abstract

Thrombotic and cardiovascular events are among the leading causes of death for patients with polycythemia vera (PV), and thrombosis history is a key criterion for patient risk stratification and treatment strategy. Little is known, however, about mechanisms of thrombogenesis in patients with PV. This report provides an overview of thrombogenesis pathophysiology in patients with PV and elucidates the roles of conventional and nonconventional thrombotic risk factors. In addition to several conventional risk factors for thrombosis, clinical data have implicated increased hematocrit and red blood cell adhesiveness, activated platelets, leukocytosis, and elevated JAK2(V617F) allele burden in patients with PV. Furthermore, PV-related inflammation may exacerbate thrombogenesis through varied mechanisms, including endothelial damage, inhibition of natural anticoagulant pathways, and secretion of procoagulant factors. These findings suggest a direct link between myeloproliferation and thrombogenesis in PV, which is likely to provide new opportunities for targeted antithrombotic interventions aimed at decreasing PV-related morbidity and mortality.

Citing Articles

Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera.

Yu J, Gayle J, Rosenthal N, Brown H, Braunstein E, Pemmaraju N Oncologist. 2025; 30(2).

PMID: 40037619 PMC: 11879438. DOI: 10.1093/oncolo/oyaf001.

The Proteome Content of Blood Clots Observed Under Different Conditions: Successful Role in Predicting Clot Amyloid(ogenicity).

Kell D, Pretorius E Molecules. 2025; 30(3).

PMID: 39942772 PMC: 11820299. DOI: 10.3390/molecules30030668.

Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative Review.

Todor S, Ichim C, Boicean A, Mihaila R Curr Issues Mol Biol. 2024; 46(8):8407-8423.

PMID: 39194713 PMC: 11353264. DOI: 10.3390/cimb46080496.

Systemic Inflammatory Index in Polycythemia Vera and Its Prognostic Implications.

Krecak I, Lekovic D, Arsenovic I, Bogdanovic A, Holik H, Zekanovic I J Clin Med. 2024; 13(15).

PMID: 39124725 PMC: 11313665. DOI: 10.3390/jcm13154459.

Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.

Haage T, Charakopoulos E, Bhuria V, Baldauf C, Korthals M, Handschuh J J Hematol Oncol. 2024; 17(1):43.

PMID: 38853260 PMC: 11163796. DOI: 10.1186/s13045-024-01562-5.

References

. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer. 1981; 44(1):75-80. PMC: 2010658. DOI: 10.1038/bjc.1981.150. View

Levine R, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P . X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal.... Blood. 2006; 107(10):4139-41. PMC: 1895292. DOI: 10.1182/blood-2005-09-3900. View

Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie B . P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A. 1994; 91(19):8767-71. PMC: 44687. DOI: 10.1073/pnas.91.19.8767. View

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S . Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011; 10(2):127-40. DOI: 10.1038/nrd3264. View

Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M . Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000; 96(13):4261-6. View

Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T . Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005; 33(5):523-30. DOI: 10.1016/j.exphem.2005.01.015. View

Passamonti F . How I treat polycythemia vera. Blood. 2012; 120(2):275-84. DOI: 10.1182/blood-2012-02-366054. View

Mackman N . New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012; 122(7):2331-6. PMC: 3386811. DOI: 10.1172/JCI60229. View

10.

Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda J, Ferrer-Marin F . Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2011; 119(6):1363-9. DOI: 10.1182/blood-2011-10-387787. View

11.

Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S . Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood. 1999; 93(8):2506-14. View

12.

Mehta J, Wang H, Fryzek J, Iqbal S, Mesa R . Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma. 2014; 55(10):2368-74. DOI: 10.3109/10428194.2013.879127. View

13.

Owens 3rd A, Mackman N . Microparticles in hemostasis and thrombosis. Circ Res. 2011; 108(10):1284-97. PMC: 3144708. DOI: 10.1161/CIRCRESAHA.110.233056. View

14.

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M . Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011; 29(6):761-70. PMC: 4979120. DOI: 10.1200/JCO.2010.31.8436. View

15.

Hultcrantz M, Kristinsson S, Andersson T, Landgren O, Eloranta S, Rangert Derolf A . Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012; 30(24):2995-3001. PMC: 3417050. DOI: 10.1200/JCO.2012.42.1925. View

16.

Passamonti F, Rumi E, Pietra D, Della Porta M, Boveri E, Pascutto C . Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2005; 107(9):3676-82. DOI: 10.1182/blood-2005-09-3826. View

17.

Aksu K, Donmez A, Keser G . Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012; 18(11):1478-93. DOI: 10.2174/138161212799504731. View

18.

Holme P, Orvim U, Hamers M, Solum N, Brosstad F, Barstad R . Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol. 1997; 17(4):646-53. DOI: 10.1161/01.atv.17.4.646. View

19.

Gangat N, Strand J, Li C, Wu W, Pardanani A, Tefferi A . Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007; 138(3):354-8. DOI: 10.1111/j.1365-2141.2007.06674.x. View

20.

Lu W, Lin K, Huang S, Thomas P, Wu Y, Wu H . Role of a Janus kinase 2-dependent signaling pathway in platelet activation. Thromb Res. 2014; 133(6):1088-96. DOI: 10.1016/j.thromres.2014.03.042. View